drugset / Trial / NCT05792462
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Phase 1/2
Recruiting
12 enrolled
Tianjin Medical University General Hospital
Tang-Du Hospital · collabThe Second Hospital of Shandong University · collab
NaSingle-groupOpen-labelBasic science
Summary
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation and differentiation. Baricitinib may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clinical trials may be needed to observe its efficacy and safety.
Timeline
- Start
- 2023-04-15
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 4 mg | Oral |